Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Read more at globenewswire.com